pharmaphorum December 15, 2025
Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage clinical testing for gout.
The deal, which includes a sizeable $950 million in upfront cash and $550 million tied to potential clinical, regulatory, and sales milestones, revolves around once-daily URAT1 inhibitor pozdeutinurad (AR882).
San Diego-based Arthrosi completed enrolment in a pair of phase 3 trials of pozdeutinurad (REDUCE 1 and REDUCE 2) earlier this year, and has said it will report results next year, with marketing applications scheduled to follow thereafter.
If the deal goes through, the acquisition will strengthen Stockholm, Sweden-based Sobi’s gout franchise, which also includes NASP (nano-encapsulated sirolimus plus pegadricase; formerly SEL-212), partnered with...
Today's Sponsors
Today's Sponsor